ID: ALA108758

Max Phase: Preclinical

Molecular Formula: C35H63NO8

Molecular Weight: 625.89

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC[C@@H]1OC(=O)[C@@H](C)C[C@H](C)CCCCC(=O)CCC[C@@H](CC)CC/C=C(\COC)CC[C@@H](O)[C@@H](O)C[C@H](O)CNC1=O

Standard InChI:  InChI=1S/C35H63NO8/c1-6-12-33-34(41)36-23-30(38)22-32(40)31(39)20-19-28(24-43-5)16-10-14-27(7-2)15-11-18-29(37)17-9-8-13-25(3)21-26(4)35(42)44-33/h16,25-27,30-33,38-40H,6-15,17-24H2,1-5H3,(H,36,41)/b28-16-/t25-,26+,27+,30+,31-,32+,33+/m1/s1

Standard InChI Key:  XDVNBGHCNXNJTA-QIHIVMKBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 625.89

Molecular Weight (Monoisotopic): 625.4554

AlogP: 5.42

#Rotatable Bonds: 5

Polar Surface Area: 142.39

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 13.68

CX Basic pKa:

CX LogP: 5.49

CX LogD: 5.49

Aromatic Rings: 0

Heavy Atoms: 44

QED Weighted: 0.23

Np Likeness Score: 1.35

References

1. Content S, Dutton CJ, Roberts L..  (2003)  Myxovirescin analogues via macrocyclic ring-closing metathesis.,  13  (3): [PMID:12565921] [10.1016/s0960-894x(02)01024-7]

2. Brown DG, Lister T, May-Dracka TL..  (2014)  New natural products as new leads for antibacterial drug discovery.,  24  (2): [PMID:24388805] [10.1016/j.bmcl.2013.12.059]

3. Brown DG..  (2016)  Drug discovery strategies to outer membrane targets in Gram-negative pathogens.,  24  (24): [PMID:27178386] [10.1016/j.bmc.2016.05.004]

Source

Source(1):

• Scientific Literature